May 13, 2020

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS… Read More
learn more